



Media Release

22 June 2010

PHARMAXIS INVESTOR CONFERENCE CALL

Pharmaxis Ltd (PXS) expects to complete its analysis and announce the results of its second international Phase III clinical trial of Bronchitol in patients with cystic fibrosis prior to the end of today, 22 June 2010. The announcement will have the effect of lifting the current trading halt over the company's shares.

The company will hold an investor teleconference at 5.00pm today to discuss the results.

Telephone access (toll free) details are below:

- Australia: 1800 838 758
- USA/Canada: 866 746 2596
- UK: 0800 376 8339
- NZ: 0800 446 958
- Switzerland: 0800 001 230
- Singapore: 800 120 4406
- Hong Kong: 800 962 283

Online access: services.choruscall.com/links/pharmaxis100622.html

A recording of the conference will be available on the Pharmaxis website home page by noon Wednesday 23 June.

SOURCE: Pharmaxis Ltd, Sydney, Australia

CONTACT: Pharmaxis Investor Relations

T: +61 2 9454 7200, F: +61 2 9451 3622,

E: Investor.Relations@Pharmaxis.com.au Website: www.pharmaxis.com.au